3 ms·
That was a narrow rejection based on incomplete evidence, as explained in the article. They were relying only on old U.S. data and still believed that the origi
by acdha 5y ago
That was a narrow rejection based on incomplete evidence, as explained in the article. They were relying only on old U.S. data and still believed that the original 2 shots were adequate protection. This was in question at the time and subsequently there’s been a clear consensus that a booster is necessary at least until the original short timing is fixed, and, of course, that was before Omicron greatly increased the risk of exposure.
- nradov 5y agoThe original 2 shots still provide good protection. Whether that's "adequate" or not is entirely subjective and arbitrary.
- s1artibartfast 5y agoI don't think that a post-hoc justification is sufficient here. Policy makers didn't have advance knowledge that the scientific experts didn't. It may have worked out in this case, but what about the next? In particular, I am concerned about the risk assessments for the <5 population. Or perhaps the next drug\therapy. Looking abroad, you will also find cases where expert panels found questionable risk/benefit for some groups and were overruled.
- acdha 5y agoMost of what I said was available at the time (not Omicron, of course). The US agencies chose not to take non-US data seriously, similarly to when the CDC acted like Delta would magically stop at the border after it was causing huge problems in the UK & India.